Summit Therapeutics

News

WCLC: Summit trumpets data with Keytruda challenger

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a bispecific antibody from Summit Therapeutics and partner Akeso looks li

News

Little Summit Therapeutics spends big bucks to rebuild pipel...

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but, in fact, it comes from diminutive biotech Summit Therapeutics.

News

Summit shares plunge nearly 80% after DMD drug fails

Summit Therapeutics has axed development of its Duchenne muscular dystrophy drug ezutromid after a spectacular failure in phase 2, causing the UK biotech's shares to plunge.

Views & Analysis

European biotech round-up: Ablynx’s big break and more

European biotech: a mixture of encouraging clinical trials and new funding lift the sector.

WCLC: Summit trumpets data with Keytruda challenger

Little Summit Therapeutics spends big bucks to rebuild pipel...

Summit shares plunge nearly 80% after DMD drug fails

European biotech round-up: Ablynx’s big break and more

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Summit Therapeutics

Editor's Picks